Key takeaways
- GHK-Cu is the copper complex of glycyl-L-histidyl-L-lysine; NAD+ is a coenzyme, not a peptide.
- GHK-Cu’s human studies are small and on skin; for NAD+, a 2026 analysis pooling four trials of NAD+ and nicotinamide riboside found no significant difference from placebo in its main outcomes.
- FDA’s 503A list (updated 14 May 2026) places GHK-Cu, for certain routes of administration only, and NAD in Category 1, “Bulk Drug Substances Under Evaluation”.
- The TGA says NAD, NAD+ and NADH “are currently not permitted ingredients” in listed medicines; the Poisons Standard October 2026 names neither GHK-Cu nor NAD+.
- Neither is named on WADA’s 2026 or 2027 List. WADA says a peptide not specifically named “may still be prohibited”; for NAD+, not a peptide, anti-doping organisations decide how the List’s classes apply.
01GHK-Cu vs NAD+ in one table
Identity, evidence and status records checked on 21 November 2026. A regulatory entry is not a verdict on every product bearing a molecule’s name.
| Question | GHK-Cu | NAD+ |
|---|---|---|
| What it is | A copper complex of the tripeptide glycyl-L-histidyl-L-lysine. | Nicotinamide adenine dinucleotide, a coenzyme; it is not a peptide. |
| Evidence tier and human data | Early human, as graded on its guide: small studies on skin, some randomised, among them one of a skin-care regimen with 13 completers (2006). Material sold online is not the formulation tested. Animal (T3) and cell (T4) work is on its guide. | Human trials are small (T1), as graded on its guide. A 2026 analysis that pooled four trials of NAD+ and nicotinamide riboside found no significant difference from placebo in its main outcomes, and a rise in a kidney marker with NAD+. |
| United States | FDA’s 503A list (updated 14 May 2026) places GHK-Cu, for certain routes of administration only, in Category 1, “Bulk Drug Substances Under Evaluation”; it is not in HHS’s October 2026 draft policy. | FDA’s 503A list places NAD in the same category. Drugs@FDA lists no product containing nadide or nicotinamide adenine dinucleotide (openFDA, 21 Nov 2026). |
| Australia | The TGA says “many products promoted online are unapproved therapeutic goods and may be unlawful to import, supply or advertise. Using unapproved peptide products can pose serious health risks.” GHK-Cu has no entry by name in the Poisons Standard October 2026, which has group entries for copper compounds; we draw no scheduling conclusion of our own. | The TGA says NAD, NAD+ and NADH “are currently not permitted ingredients” in listed medicines (safety alert, last updated 3 Feb 2026). The Poisons Standard October 2026 does not name it; we draw no scheduling conclusion of our own. |
| United Kingdom | The emc medicines database returned no results for GHK, copper tripeptide or prezatide (21 Nov 2026); it is not the full UK register. | The emc database returned no results for nadide or nicotinamide adenine dinucleotide (21 Nov 2026); it is not the full UK register. |
| Sport | Not named on the 2026 or 2027 List. WADA says a peptide not specifically named “may still be prohibited”. | Not named on the 2026 or 2027 List. The List’s classes include substances it does not name, and anti-doping organisations decide how they apply. |
For the next evidence question, read the GHK-Cu research guide. To learn what a lot-specific lab report can and cannot establish, see how to read a COA.
02How do their identities differ?
GHK-Cu names a complex: copper bound to GHK, a chain of three amino acids. The “Cu” identifies the copper component. That molecular description is not proof of what a particular vial contains.
NAD+ stands for nicotinamide adenine dinucleotide. It is a coenzyme, not a peptide. Calling both substances “peptides” would blur a basic difference in molecular identity.
GHK
Three amino acids form the peptide part of the name.
GHK-Cu
The name describes GHK associated with copper; a label alone does not verify vial contents.
NAD+
A different molecular class. It is not a chain of amino acids.
03What can the evidence comparison tell you?
Evidence tiers describe particular studies, not a universal score for a molecule. GHK-Cu has small human studies on skin as well as cell and animal research. Human studies vary in design and context, so a short label such as “human evidence” cannot stand in for a study-by-study account.
NAD+ has its own small trials, graded T1 on its guide; they measured different things in different people from the GHK-Cu skin studies. Putting both on one scale would imply a comparison that no study has made.
If you searched “nad vs ghk cu,” the clearest answer is that their identities differ, while the evidence needs separate assessment. A study of one does not establish findings about the other. Nor does a molecule’s name confirm the identity or contents of material sold under that name.
Check whether a paper studied GHK-Cu, NAD+, a related molecule or a different formulation.
Separate cell, animal and human studies. Then check what each study measured and what it did not.
A finding in one study does not establish a general effect or a ranking between these molecules.
04What do the regulatory records say?
The table gives what each document says on the date shown. None is a legal conclusion of ours.
United States. FDA’s 503A list (updated 14 May 2026) places GHK-Cu, for certain routes of administration only, and NAD in Category 1, which FDA labels “Bulk Drug Substances Under Evaluation”. FDA has said it intends to consult its Pharmacy Compounding Advisory Committee on GHK-Cu before the end of February 2027.
Australia. The TGA says “many products promoted online are unapproved therapeutic goods and may be unlawful to import, supply or advertise. Using unapproved peptide products can pose serious health risks.” Neither GHK-Cu nor NAD+ is named in the Poisons Standard October 2026, which has group entries for copper compounds; separately, the TGA says NAD, NAD+ and NADH “are currently not permitted ingredients” in listed medicines. We draw no scheduling conclusion of our own.
United Kingdom. The emc medicines database returned no results for GHK, copper tripeptide, prezatide, nadide or nicotinamide adenine dinucleotide (21 November 2026). It is not the full UK register.
Sport. Neither is named on WADA’s 2026 or 2027 List. WADA says a peptide not specifically named “may still be prohibited”, and that a substance not found on the List should be checked with your anti-doping organisation.
05What we don’t know
- Any study that compared GHK-Cu with NAD+: we found none (PubMed, 21 November 2026).
- Whether the small GHK-Cu skin studies or the small NAD+ trials say anything beyond the people and measures they studied.
- How anti-doping organisations would apply the List’s classes to either molecule, since the List names neither.
- What a particular vial contains: a name or a regulatory entry cannot establish that.
This is a plain-English summary of selected public records, checked on 21 November 2026. It is not legal or medical advice.